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Angiogenesis related genes NOS3, CD14, MMP3
and IL4R are associated to VEGF gene expression
and circulating levels in healthy adults
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Abstract
Background: Vascular endothelial growth factor (VEGF) plays a key role in angiogenesis. The aim was to assess the
genetic connections between the angiogenesis-related NOS3, CD14, MMP3, IL4R, IL4 genes and VEGF expression and
plasma levels.
Methods: The associations between VEGF plasma levels with the polymorphisms of NOS3, CD14, MMP3, IL4R, and
IL4 were assessed in 403 healthy unrelated adults. The epistatic and environmental interactions were explored, including
four VEGF-related polymorphisms previously identified. The VEGF expression in peripheral blood mononuclear cells was
quantified (n = 65) for the VEGF121, VEGF145, VEGF165, and VEGF189 isoforms.
Results: The polymorphism rs1799983 of NOS3 was associated with the sum of all VEGF isoforms mRNA levels (P = 0.032)
and VEGF145 (P = 0.033). Rs1800779 of NOS3 interacted with rs3918226 of the same gene and with the rs2569190 of
CD14 (P = 0.022, P = 0.042, respectively) for VEGF plasma levels. Other epistatic interactions included the rs1801275 of IL4R
with the rs6921438 (VEGF-related variant) and rs3025058 of MMP3 (P = 0.042, P = 0.010 respectively) and the rs2569190 of
CD14 with the rs3025058 of MMP3 (P = 0.0119). We also identified an interaction of rs1800779 with obesity, high-density
lipoprotein cholesterol and triglycerides (P = 0.018, P = 0.005, P = 0.043, respectively) as well as the interaction of
rs6921438 with hypertension (P = 0.028).
Conclusions: Our findings indicated that genetic variants of NOS3, CD14, MMP3 and IL4R are implicated in the
determination of VEGF expression and plasma levels. Thus, they support the hypothesis that in physiological conditions
there are complex biological relationships between pathways (such as angiogenesis and inflammation), which are
involved in the development of chronic diseases.
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Background
Angiogenesis is the procedure of development of new ves-
sels from the existing vasculature. One of the most potent
angiogenesis regulators is the vascular endothelial growth
factor A (VEGF-A or more commonly known as VEGF).
VEGF is a highly conserved, disulfide-bonded dimeric
glycoprotein of 34–46 kDa. It is generated by several cell
types including neutrophils, macrophages, fibroblasts, per-
ipheral blood mononuclear cells (PBMCs) and endothelial
cells. Elevated circulating VEGF levels have been associ-
ated with several types of cancer and other chronic dis-
eases including cardiovascular diseases (ischemic heart
disease, heart failure, stroke), diabetes, immune and in-
flammatory disorders [1–3].
Other regulators of angiogenesis include the nitric oxide
synthase (NOS3), the CD14
+ monocytes, the matrix metal-
loproteinases (MMPs), and the interleukin 4 (IL4).
NOS3 provides continuous local production of nitric
oxide (NO). NO is an important angiogenesis mediator
and/or effector also involved in endothelial function and
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thereby can influence vascular tonicity, insulin resist-
ance, development of atherosclerosis and type 2 diabetes
[4, 5]. The increase in NO production via up regulation
of NOS3 by VEGF indicates that the angiogenic effect of
VEGF seems to be mediated by NO [6–8]
CD14+ monocytes are abundant in human peripheral
blood and have strong potential to differentiate into endo-
thelial cells [9]. CD14 is a multifunctional receptor and
contributes to different biological and pathophysiological
processes including apoptosis, sepsis, inflammatory dis-
eases, angiogenesis and tumor growth. Therefore, CD14
has been demonstrated to be a candidate for developing
anti-cancer medications in tumor growth and angiogen-
esis [10].
The MMPs are zinc-dependent proteinases with an
ability to degrade enzymes [11]. They are involved in
pathologic conditions characterized by excessive degrad-
ation of extracellular matrix, such as tumor metastasis,
and arteriosclerosis [12]. Several pieces of evidence indi-
cate associations between MMPs and VEGF and a link
of MMPs with angiogenesis [12–18].
The IL4 is a glycoprotein secreted by activated T
lymphocytes, basophils and mast cells [19]. Previous
studies have indicated the involvement of IL4 in
angiogenesis [20, 21].
These molecules are implicated in a variety of biological
procedures in both health and disease. The precise mecha-
nisms involving these molecules in angiogenesis in differ-
ent conditions are under investigation. However, due to
their complexity, interpreting the origin of their biological
connections is challenging. Therefore, their evaluation in
the healthy state is believed to provide important informa-
tion concerning the physiological relationships between
these molecules before the development of a specific dis-
ease. For this reason, the current study was performed in a
supposed healthy population, aiming to examine possible
genetic links between angiogenesis related (NOS3, CD14,
MMP3, and IL4) candidate genes and VEGF plasma levels
and gene expression in the healthy state. This assessment
could provide evidence of functionally angiogenesis-related
polymorphisms. Furthermore, gene-gene (epistatic) and
gene-environment interactions effects on VEGF plasma
levels were also investigated. Those interaction analyses
included 4 polymorphisms significantly associated with
VEGF plasma levels in a previous genome-wide associ-
ation study (GWAS), and explaining up to 50 % of its
inter-individual variability [3]. In silico structural analyses




The STANISLAS Family Study is a 10-year longitudinal
survey involving 1,006 families from Vandoeuvre-lès-
Nancy, France between 1993–1995 [22]. Exclusion criteria
included the presence of chronic disorders (cardiovascular
diseases or cancer) and the personal history of cardiovas-
cular disease. The study protocol was approved by the
Local Ethics Committee of Nancy and all subjects gave
written informed consent. Four hundred and three unre-
lated adults collected during the second examination of
the STANISLAS Family Study were selected based on
complete availability of data.
Data collection and biological measurements
The procedures of data collection have been previously
described [22, 23]. Blood samples were collected after
overnight fasting. Sodium EDTA-plasma was separated
by centrifugation at 2000 g for 15 min at 4 °C and stored
at −196 °C in liquid nitrogen until analysis. VEGF
plasma levels were quantified by Randox Ltd (Crumlin,
UK) using a biochip array analyser (Evidence ®) [24].
Total cholesterol (TC) was measured using a cholesterol
oxidase-paraaminophenazone method, triglycerides using a
glycerophosphate oxidase/paraaminophenazone alanylgly-
cine glycine method, and high-density lipoprotein choles-
terol (HDL-C) levels using a phosphotungstate method,
while low-density lipoprotein cholesterol (LDL-C) levels
were calculated using the Friedewald formula [25].
Hypertension was defined as systolic blood pres-
sure ≥140 mm/Hg or diastolic blood pressure ≥90 mm/
Hg. Body mass index (BMI) was calculated as weight
(kilograms) divided by height (meters) squared. Obesity
was defined as BMI ≥30 kg/m2. Smokers were identified
based on current smoking status.
SNP selection
The single nucleotide polymorphisms (SNPs) rs2569190,
rs2243250, rs2010963, rs3918226, rs1799983, rs1800779,
rs3025058, rs1805015 and rs1801275 of the NOS3, CD14,
MMP3, IL4R, and IL4 genes (Table 1) were selected on
the basis of their functionality on the related genes.
The SNPs rs6921438, rs4416670, rs6993770, and
rs10738760, previously shown to be associated with VEGF
levels [3], were used for the testing of epistatic effects.
DNA isolation and genotyping
The genomic DNA was isolated using the salting out
method [26]. The polymorphisms rs2569190, rs2243250,
rs2010963, rs3918226, rs1799983, rs1800779, rs3025058,
rs1805015 and rs1801275 of the NOS3, CD14, MMP3,
IL4R and IL4 genes were genotyped using multilocus
genotyping assays previously described [27, 28]. The
VEGF-related SNPs were genotyped by Genoscreen
(http://genoscreen.fr), using a Sequenom iPLEX Gold
assay–Medium Throughput Genotyping Technology [29].
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Gene expression assays
Total RNA was extracted from PBMCs in a subsample
of 65 subjects with a MagNaPure automate, using the
MagNA Pure LC RNA HP isolation kit and RNA HP
Blood External lysis protocol [Roche Diagnostics,
France]. Reverse transcription of total RNAs were per-
formed using 200 units of M-MuLV Reverse Transcript-
ase with 0.25 μg of oligos (dT) (Promega, France) as
previously described [30]. Quantification of the tran-
scripts coding for the VEGF isoforms (VEGF121,
VEGF145, VEGF165, VEGF189), the beta 2 microglobulin
(β2M) control gene were performed using TaqMan® and
LightCycler technologies (LC TaqMan Master Kit, Roche
Diagnostics, France) in duplicate. RT-PCR optimization
and specificity of Real Time-PCR products were con-
ducted using SYBR® Green technology (LC FastStart
DNA MasterPLUS SYBR Green I kit, Roche Diagnostic,
France), melting curves analysis and agarose gel electro-
phoresis of the PCR amplicons [30]. All mRNA levels
were normalized to the mRNA levels of β2M gene. Total
VEGF mRNA derived from the sum of the ratio of the
four isoforms present in PBMCs.
Computational structural analyses
The polymorphism rs1799983 allows the generation of two
isoforms of endothelial NOS3: eNOS3 Glu298 (allele G)
and eNOS3 Asp298 (allele T). This gene is located on
chromosome 7 q36.1. It contains 26 coding exons extend-
ing on approximately 24 kb. Multiple transcript variants
encode different isoforms (Fig. 1). Canonical isoform codes
for an enzyme of 1203 amino acids. The active protein is a
homodimer (chains A and B) catalyzing from L-arginine
the formation of NO. The polymorphism rs1799983 is
located on the coding exon 7 of NOS3 and has been previ-
ously identified by Yoshimura et al. as a Glu298-to-Asp
variant [31].
Sofowora et al. found that eNOS3 Asp298 homozy-
gotes excreted significantly less nitrate/nitrite than
eNOS3 Glu298 homozygotes [32]. As amino acid in
position 298 does not belong to the catalytic residue
of the enzyme active site (formed by Arg187 (A) –
Cys184 (A) – Glu361 (A) – Trp356 (A)) a question
remains: how this rs1799983G > T can affect nitric
oxide production and how can this be linked with
VEGF?
Table 1 Characteristics of the studied polymorphisms
Chromosome SNPs Minor allele Common allele Closed to/on gene Minor allele Frequency HWE aP
5 rs2569190 G A CD14 molecule 0.48 0.8332
5 rs2243250 T C IL4 interleukin 4 0.15 0.6865
6 rs4416670 C C MGC45491 and MRPL14 (near VEGF) 0.47 0.5489
6 rs2010963 C G VEGFA 0.35 0.3243
6 rs6921438 A G MGC45491 and MRPL14 (near VEGF) 0.4 1
7 rs3918226 T C NOS3 nitric oxide synthase 3 0.09 0.3379
7 rs1799983 T G NOS3 nitric oxide synthase 3 0.35 0.7309
7 rs1800779 G A NOS3 nitric oxide synthase 3 0.4 0.6624
8 rs6993770 T A ZFPM2 0.28 0.9019
9 rs10738760 G A VLDLR and KCNV2 0.48 0.9205
11 rs3025058 - T MMP3 matrix metallopeptidase 3 0.48 1
16 rs1805015 C T IL4R interleukin 4 receptor 0.13 0.3821
16 rs1801275 G A IL4R interleukin 4 receptor 0.18 0.8632
aHardy Weinberg Equilibrium
Fig. 1 Schematic organisation of eNOS3 transcripts in chromosome 7. Rs1799983 is indicated with the orange triangle. Exons are represented by
rectangular shapes and coding exons are coloured
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Structural analyses were performed using the crystallo-
graphic structure of the human endothelial nitric oxide syn-
thase, oxygenase domain [33]. Conformational changes in
nitric oxide synthases induced by chlorzoxazone and
nitroindazoles were assessed through crystallographic and
computational analyses of inhibitor potency [33]. Computa-
tional analyses for the building of a model of NOS3
Asp298 were performed using the I-Tasser suite [34, 35]
and Pymol software was used to analyze structural features
(the PyMol Molecular Graphics System, Schrodinger, LLC).
Statistical analyses
VEGF plasma concentrations and mRNA values were
log-transformed, before the analyses, to normalize their
distribution. Hardy-Weinberg equilibrium was tested
using the chi-square test.
The associations between the SNPs of NOS3, CD14,
MMP3, IL4R and IL4 genes and VEGF plasma and ex-
pression levels were assessed through linear regression
adjusted for age, gender and BMI under an additive
model and using the minor allele as reference allele.
The epistatic interactions between the polymorphisms of
NOS3, CD14, MMP3, IL4R and IL4 genes and the VEGF-
related SNPs for VEGF plasma levels were tested using the
linear models described before with the introduction of the
interaction term of a 2 × 2 combination between the
assessed SNPs. For example VEGF~ age + gender + BMI +
SNP1 + SNP2 + SNP1 × SNP2. The environmental factors
used for the SNPs × environment interactions included
smoking, blood lipids levels, obesity, and hypertension. We
used linear regression models adjusted for age, gender,
BMI (when obesity was the assessed factor, adjustments
were performed only for age and gender), the environmen-
tal factor, and the additional interaction term (SNP × envir-
onmental factors). The interaction analyses were not
performed for VEGF gene expression data due to the lim-
ited sample size. Analyses were performed using PLINK
1.07 (http://pngu.mgh.harvard.edu/purcell/plink) [36] and
the SPSS 17.0 (SPSS, Inc, Chicago, Illinois) statistical soft-
wares. Significance was determined at a two-tailed P = 0.05
level.
The sample size calculation was performed using the
software QUANTO. Based on published information about
allele frequencies of the selected polymorphisms, the levels
of VEGF in plasma and its expression, and an estimation
of a mild effect size, a number of 400 individuals would be
sufficient in order to achieve a statistical power of 80 %.
Results
The studied polymorphisms are presented in Table 1. All
SNPs were in agreement with Hardy-Weinberg equilib-
rium (P > 0.05). The characteristics of the studied popu-
lation are summarized in Table 2 (Additional file 1:
Tables S1 and S2).
Association of the assessed polymorphisms of the NOS3,
CD14, MMP3, IL4R and IL4 genes with VEGF gene
expression and plasma levels
After adjustment for age, gender and BMI, a significant as-
sociation was observed between rs1799983 of NOS3 and
the sum of all VEGF isoforms mRNA and VEGF145
mRNA (β = 0.19, P = 0.032 and β = 0.17, P = 0.033 respect-
ively). None of the polymorphisms of the NOS3, CD14,
MMP3, IL4R and IL4 genes were associated with VEGF
plasma levels.
Epistatic interactions between NOS3, CD14, MMP3, IL4R,
IL4 and VEGF-related polymorphisms on the plasma levels
of VEGF
Six genetic variants were involved in epistatic interactions
for VEGF plasma levels regulation, including rs1800779
and rs3918226 (NOS3), rs2569190 (CD14), rs3025058
(MMP3), rs1801275 (IL4R) and rs6921438 (VEGF)
(Table 3). Specifically, the interaction of rs1800779 of
NOS3 with rs3918226 of the same gene was associated
with increased VEGF plasma levels (β = 0.17, P = 0.022)
and the interaction with the rs2569190 of CD14 (β = −0.06,
P = 0.042) was associated with decreased VEGF plasma
levels. Therefore, the SNP rs1800779 of NOS3 has a modi-
fiable effect on VEGF plasma levels though epistatic inter-
actions with different polymorphisms. Additionally the
Table 2 Characteristics of study population (n = 403)
Variable Meana SDb
Age (years) 44.4 4.8
Gender (%) male 50.4
Body mass index (kg/m2) 24.9 3.9
Vascular endothelial growth factor (pg/ml) 42.7 43.3
Total cholesterol (mmol/l) 5.7 1.0
Triglycerides (mmol/l) 1.3 1.2
High- density lipoprotein (mmol/l) 1.6 0.4
Low-density lipoprotein (mmol/l) 3.5 0.8
Obesity (%) 7.9 %
Smoking (%) 25.4 %
Hypertension (%) 5.7 %
aMean values for continuous variables and percentages for
categorical variables
bSD standard deviation
Table 3 Epistatic interactions for VEGF plasma levels
SNP × SNP Genes β a(pg/ml) t-values P
rs1800779 × rs2569190 NOS3 × CD14 −0.07 −2.04 0.042
rs1800779 × rs3918226 NOS3 × NOS3 +0.17 2.29 0.022
rs1801275 × rs6921438 IL4R × VEGF +0.08 2.043 0.042
rs1801275 × rs3025058 IL4R ×MMP3 −0.10 −2.58 0.010
rs2569190 × rs3025058 CD14 ×MMP3 +0.07 2.36 0.019
a β, effect size
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rs1801275 of IL4R interacted with the VEGF-related SNP
rs6921438 resulting in an increase of VEGF plasma levels
(β = 0.07, P = 0.042) and with the rs3025058 ofMMP3 with
a decreasing effect (β = −0.09, P = 0.010). Again, in this
case, the rs1801275 has different effects on VEGF plasma
levels depending on interactions with different polymor-
phisms of angiogenesis-related genes. Finally, the inter-
action between rs2569190 of CD14 and rs3025058 of
MMP3 was associated with a significant increase in plasma
levels of VEGF (β = 0.07, P = 0.019).
SNPs × environmental interactions on the plasma levels of
VEGF
Significant interactions were observed between NOS3
SNPs and HDL-C, triglycerides and obesity (Table 4).
A decrease of VEGF plasma levels resulted from the
interaction of rs1800779 with obesity and triglycerides
(β = −0.11, P = 0.018, β = −0.04, P = 0.043 respectively),
while its interaction with HDL-C was associated with
an increase in VEGF plasma levels (β = 0.12, P =
0.005). Furthermore, the VEGF-related polymorphism
rs6921438 interacted with hypertension to decrease
VEGF levels (β = −0.18, P = 0.028).
Structural analyses of NOS3 gene
The study of NOS3 domains revealed that the amino
acid in position 298 is located in NOS-Interacting Pro-
tein (NOSIP) binding domain (amino acids 98–498).
Moreover, this binding domain overlaps the oxygenase-
domain containing active site (Fig. 2).
Comparative analyses of the crystal structure of the
human eNOS3 oxygenase domain (pubmedcode
:1M9M −1.96 Å resolution – Figs. 3 and 4) with the
computed eNOS3 Asp298 reveals conformational
changes between eNOS3 Glu298 and eNOS3 Asp298.
Indeed, the amino acid in position 298 is not buried but
exposed on the surface. Thereby, eNOS3 shows a pro-
tuberance when it is composed of Glu298 whereas
eNOS3 model removes this relief with aspartate amino
acid. (Figs. 5 and 6).
Discussion
In the present study, we have identified significant asso-
ciations between genetic variants of NOS3 with VEGF
gene expression in a healthy population. Furthermore,
significant epistatic and gene × environment interactions
have been identified for VEGF plasma levels involving
polymorphisms of NOS3, CD14, MMP3, IL4R and
VEGF-related SNPs.
Numerous SNPs have been identified in NOS3 gene,
among them, the common variant, G984T (rs1799983).
It is located in exon 7 of the gene, and it modifies its
coding sequence, thus resulting in an amino acidic sub-
stitution of glutamic acid to aspartic acid at position 298
of the protein. It has been reported to alter its enzymatic
activity [37, 38]. This SNP has been demonstrated by
several groups to be linked with the risk for coronary
spasm, coronary artery disease and acute myocardial in-
farction [39–43].
In this study, a significant association between the SNP
rs1799983 and VEGF expression level (total mRNA and
VEGF145 isoform) was observed. The minor allele of this
SNP was associated with increased levels of VEGF mRNA.
Such association might suggest the existence of transcrip-
tional regulation of VEGF from NOS3 in PBMCs in non-
pathological situations and thus a novel molecular link
between VEGF and NO. It is noteworthy that in a previ-
ous investigation, we had identified significant associations
between the VEGF145 isoform with cellular adhesion and
inflammation molecules expression (ICAM-1, L-selectin
and TNF-a) in the same population [44]. Our current re-
sults further support the importance of this isoform on
cardiovascular physiology and underline its potent role as
a key molecule in different diseases.
There are few pathways leading to the synthesis of NO.
One of them consists in the formation of the complex
eNOS3/caveolin-1. However, a protein avidly binding to
the eNOS oxygenase domain termed NOSIP [45] has been
identified. When NOSIP binds to eNOS3, eNOS is seques-
tered in the Golgi apparatus decreasing NO production in
eNOS3 Asp298 homozygotes [32]. It is therefore likely that
eNOS3 298 Asp promotes formation of a complex with
NOSIP. In this context, homozygotes eNOS3 298 Asp
probably synthesize NO via alternative pathways involving
VEGF/PI3K/Akt [46]. Thus, to compensate this engage-
ment to this preferred pathway of complex formation with
NOSIP for homozygotes eNOS3 Asp298, the physiological
response to NO production is the increase of VEGF ex-
pression levels, known to stimulate the synthesis of NO via
eNOS3 on the one hand but also via VEGF/PI3K/Akt.
Table 4 Significant gene x environment interactions with VEGF plasma levels
Interaction Gene β a(pg/ml) t-values P
rs1800779 × HDL-C NOS3 0.12 2.78 0.005
rs1800779 × Triglycerides NOS3 −0.04 −1.98 0.043
rs1800779 × Obesity NOS3 −0.11 −2.36 0.018
rs6921438 × Hypertention MGC45491 and MRPL14(near VEGF) −0.18 −2.20 0.028
a β, effect size
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Therefore, our structural analyses offer an explanation of
the link between the SNP rs1799983 and VEGF expression
level.
On the other hand, no significant relations were found
between VEGF gene expression and/or plasma levels
and CD14, MMP3, IL4R and IL4 polymorphisms in our
healthy population.
In this study, we also observed an epistatic interaction
between NOS3 SNP rs1800779 and CD14 SNP rs2569190
which resulted in a significant decrease in VEGF plasma
level. The rs1800779 is located in the upstream and pro-
moter region of the gene and may eventually lead to re-
duced production and bioavailability of NO. Also, the
CD14 SNP rs2569190 is situated at position −159 of the
gene and has been suggested to be linked with increased
expression and transcriptional activity of CD14 [47].
Additionally, we have found that the interaction be-
tween the NOS3 SNPs rs1800779 and rs3918226, was as-
sociated with a significant increase in VEGF plasma
level. Similar to the former SNP, the rs3918226 is located
in the promoter region of NOS3 gene. Although no
functional studies have been reported so far for this SNP,
few studies have identified a transcription-factor binding
site for the ETS-family next to rs3918226, suggesting
that rs3918226 can potentially modulate the expression
of NOS3 [48].
It is important to mention that the epistatic interaction
between IL4R SNP rs1801275 and the VEGF-related
SNP rs6921438 was associated with a significant increase
in VEGF plasma level in our healthy population. IL4
biological actions are mediated by its binding to the re-
ceptors IL4, which leads to the activation of intracellular
signaling pathways [49]. The IL4R SNP rs1801275 is a
substitution of Arg with Gln at the position 576 of the
protein, resulting in an enhancement in the receptor sig-
naling. In addition, the VEGF-related SNP rs6921438 is
an intergenic variant that is located at 171 kb down-
stream of the VEGF gene on chromosome 6p21.1. In a
previous GWAS, the minor allele of the polymorphism
was associated with decreased VEGF levels [3]. The
mechanism of this interaction is not known and as few
data are available in the literature, the biological explica-
tion of this epistatic effect cannot be hypothesized.
Complex relationships have been observed between IL4
and VEGF in several diseases. IL4 has pro-angiogenic and
pro-inflammatory properties in the lungs during exposure
to chronic hypoxia, an effect dependent on the hypoxia-
mediated induction of the VEGF signaling pathway [50].
Fig. 2 Domains’ organisation of human eNOS3 enzyme. Position of rs1799983 is indicated (Glu298Asp). NA: NADP-nucleotide phosphate-binding
region, Cal: calmodulin-binding-region
90°
Fig. 3 Representation of the dimeric form of eNOS3 oxygenase domains (PDB : 1M9M). Chain A is in green and chain B is represented in cyan for
alpha helix and magenta for beta strands. Glu298Asp corresponding to rs1799983, is depicted in red in each chain
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Also, IL4 has been discovered to exert anti-angiogenic
properties in several cancer models with high VEGF ex-
pression levels [51]. Moreover, in patients with rheuma-
toid arthritis, IL4 inhibits VEGF production in synovial
fibroblasts [7]. The results of our study support the con-
cept of crosstalk between VEGF and IL4.
Another finding of our investigation indicates an epi-
static interaction between the IL4R SNP rs1801275 and
MMP3 SNP rs3025058 that was associated with a signifi-
cant decrease in VEGF plasma level. TheMMP3 SNP is lo-
cated in the promoter region of the gene where the one
allele has a run of six adenosines (6A) and another having
five adenosines (5A) at position 1171 [52]. It has been
shown that MMPs are involved in different steps of angio-
genesis and play an important role in the blood vessel
growth and the process of vascular development in cancer
[53]. In addition, MMPs can increase the bioavailability of
VEGF [54]. The association between MMPs and VEGF has
been demonstrated, in several studies, to contribute to dif-
ferent pathological conditions, e.g. cancer invasion [15–17].
Therefore, considering the potential interactions of VEGF
with both IL4 and MMPs, it is not surprising that in this
study we observed a significant interaction between IL4R
and MMPs for VEGF plasma levels.
Hypertension, smoking, blood lipids and obesity were
the “environmental factors” selected for interaction ana-
lyses, as they are risk factors with large environmental
impact for different diseases, especially cardiovascular
diseases. We observed interactions between NOS3 SNP
rs1800779 with HDL-C, triglycerides and obesity. These
interactions were associated with increased VEGF
plasma levels in the case of HDL-C, and decreased
VEGF levels for triglycerides and obesity. Loebig et al.
reported a positive correlation between plasma VEGF
concentrations in overweight subjects as compared with
normal and low weight individuals. However, they did
not find any significant differences of VEGF levels when
comparing normal and low weight participants [6].
Sandhofer et al., found that the plasma levels of VEGF
are positively and negatively correlated with BMI in
men, and visceral fat in women respectively [55]. Our in-
teractions results indicate that the relationship between
VEGF and adiposity could be mediated by NOS3 vari-
ants, through interactions with the adiposity indexes.
90° 90°
Fig. 4 Representation of solvent-accessible surface area of eNOS3 homodimer oxygenase domains (PDB :1M9M). Chain A and B are in green and
cyan respectively. Glu298 is coloured in magenta in both chains
90°
Fig. 5 NOS3 Glu298 [1m9m]
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Finally, we identified an interaction of the SNP
rs6921438 with hypertension, which was associated with
a decrease in VEGF levels. As previously mentioned, the
minor allele of this variant was associated with de-
creased VEGF levels [3] and explained 41 % of the VEGF
inter-individual variability. Furthermore, it was the only
polymorphism among the 4 VEGF-related assessed in
the present study that was implicated in epistatic and
environmental interactions for VEGF. Therefore, it
seems that its role as a VEGF biomarker may be even
more significant through indirect interactions as well.
Moreover, the same variant has been also recently found
to contribute to decreased HDL-C and increased LDL-C
levels in the same population [56]. Thus, it could repre-
sent a strong biological link between angiogenesis, blood
pressure regulation and blood.
The findings of this study are original and they are
providing initial evidences on the field of functional vari-
ants implicated in angiogenesis regulation, through dir-
ect effects or interactions, in health. A limitation of the
study is the use of nominal significance threshold for the
production of the results. This is the most common
practice in the candidate genes studies, where a limited
number of SNPs are assessed, like the present one. Un-
derstanding this limitation, we have performed structural
analyses and provide functional biological evidences for
some of these results. Furthermore, we acknowledge the
need for replication of our results in larger population.
Conclusions
In the present work, we assessed the associations of
VEGF plasma levels and gene expression with NOS3,
CD14, MMP3, IL4R, IL4 and VEGF-related SNPs in a
healthy population, as well as their epistatic and envir-
onmental interactions. The significant role of a func-
tional NOS3 polymorphism on VEGF gene expression
was presented and biological confirmation was provided
though structural analyses of NOS3 gene. VEGF plasma
levels were also affected by epistatic and environmental
interactions with polymorphisms of the NOS3, CD14,
MMP3, and IL4R. Among the VEGF-related polymor-
phisms, the stronger VEGF determinant, rs6921438, was
also implicated in such interactions modulating VEGF
levels. These results indicate the central role of VEGF
regulation in different physiological biological proce-
dures and support the existence of complex relationships
between angiogenesis, NOS3, CD14, MMP3 and IL4R
that exist even in the healthy state. Such complex inter-
actions should be taken into account in future studies
concerning the implication of VEGF in related human
chronic pathologies. The understanding of these associa-
tions may promote the knowledge of the molecular
mechanisms and the processes that mediate complex
diseases such as diabetes, cancer and cardiovascular dis-
eases. Also the possible development of new therapeutic
targets in a personalized medicine approach can also be
considered. Furthermore, this study underlines the value
of candidate gene approach in combination with GWAS
in assessing interactions of the biological determinants
of disease intermediate phenotypes such as the VEGF.
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